Financial Performance - The total revenue for the year ended December 31, 2024, was RMB 7,574,756,000, representing an increase of 14.2% compared to RMB 6,634,992,000 in 2023[4] - Gross profit for the same period was RMB 3,682,832,000, up from RMB 3,482,239,000, indicating a growth of 5.7%[4] - Operating profit increased to RMB 1,086,382,000, a rise of 15.3% from RMB 941,598,000 in the previous year[4] - Net profit for the year was RMB 879,537,000, compared to RMB 776,130,000 in 2023, marking an increase of 13.3%[4] - Basic and diluted earnings per share rose to RMB 1.27 from RMB 1.16, reflecting a growth of 9.5%[4] Assets and Liabilities - Non-current assets increased to RMB 5,849,059,000 from RMB 4,997,241,000, a growth of 17.1%[6] - The company's total assets less current liabilities reached RMB 9,743,980,000, up from RMB 8,937,789,000, indicating an increase of 9.0%[6] - The total equity attributable to shareholders increased to RMB 5,005,301,000 from RMB 4,693,320,000, representing a growth of 6.6%[7] - Trade receivables as of December 31, 2024, totaled RMB 5,155,122,000, an increase of 26.4% from RMB 4,080,997,000 in 2023[30] - Current assets decreased slightly by 1.2% from RMB 3,940.5 million in 2023 to RMB 3,894.9 million in 2024, mainly due to a reduction in cash and an increase in bank loans[98] Revenue Breakdown - The revenue from radiopharmaceutical sales was RMB 4,167,606,000 in 2024, up from RMB 4,017,476,000 in 2023, reflecting a growth of 3.7%[14] - The revenue from nuclear medical equipment sales increased to RMB 912,477,000 in 2024, compared to RMB 706,124,000 in 2023, marking a growth of 29.2%[14] - The group’s revenue from technical services rose to RMB 552,522,000 in 2024, up from RMB 349,390,000 in 2023, representing an increase of 58.2%[14] - The revenue from irradiation services was RMB 172,788,000 in 2024, compared to RMB 161,687,000 in 2023, showing a growth of 6.9%[14] - The group’s revenue from medical device sales increased to RMB 801,650,000 in 2024, up from RMB 544,690,000 in 2023, reflecting a growth of 47.0%[14] Expenses and Costs - Total other income for 2024 was RMB 77,518,000, a significant decrease of 67.8% compared to RMB 240,928,000 in 2023[23] - Total employee costs for 2024 were RMB 886,024,000, up from RMB 867,378,000 in 2023, reflecting a rise of 2.0%[25] - Sales cost rose by 23.4% from RMB 3,152.8 million in 2023 to RMB 3,891.9 million in 2024, primarily due to increased sales costs in nuclear medical equipment and related services[86] - Administrative expenses, R&D costs, and credit impairment losses increased by 3.7% from RMB 1,013.2 million in 2023 to RMB 1,050.3 million in 2024, while the percentage of these costs to revenue decreased from 15.3% to 13.9%[90] - Financial expenses grew by 34.0% from RMB 36.1 million in 2023 to RMB 48.4 million in 2024, primarily due to increased external borrowing for funding needs[91] Dividends and Shareholder Information - The company proposed a final dividend of RMB 0.309 per share for 2024, slightly down from RMB 0.3131 per share in 2023[29] - The expected payment date for the final dividend is before August 2, 2025[131] - Shareholders listed on June 12, 2025, will receive the final dividend for the fiscal year 2024, pending approval at the annual meeting[134] Research and Development - Research and development expenses were RMB 300,286,000, slightly down from RMB 306,051,000 in 2023, showing a decrease of 1.5%[4] - The group applied for 274 patents and obtained 224 patent grants during the reporting period, enhancing its technological capabilities[48] - The company has a talent pool of 507 R&D personnel, including 1 foreign expert, 9 national-level talents, and 11 provincial-level talents, focusing on production technology optimization and new product development[58] Market Expansion and Collaborations - The group is actively expanding its international market presence, participating in various global industry conferences to enhance brand recognition[46] - The company is committed to supporting the "Healthy China" strategy by providing comprehensive solutions for nuclear medicine and radiation therapy[65] - The company is actively pursuing international collaborations and expanding its product offerings in the nuclear medicine sector, including the introduction of new isotopes[42] Corporate Governance and Compliance - The company has complied with the Corporate Governance Code and has established a modern corporate governance framework[124] - The Audit and Risk Management Committee has reviewed the consolidated financial results for the year ending December 31, 2024[126] - The company has not disclosed any significant adverse changes in its financial and operational conditions as of December 31, 2024[111]
中国同辐(01763) - 2024 - 年度业绩